Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 12, 2026
- Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.
- 10-Q report · filed Nov 12, 2026
- Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.
The audio replay and transcript follow the call.